首頁 > 市場調查報告書 > 製藥

循環系統

市場調查報告書

商品編碼

2077343

慢性腎病高血壓市場：按藥物類別、分銷管道和地區分類

Hypertension in CKD Market, By Drug Class, By Distribution Channel, By Geography

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

與慢性腎臟病(CKD) 相關的高血壓市場預計在 2026 年達到 3.452 億美元，預計到 2033 年將達到 7.122 億美元。預計從 2026 年到 2033 年，該市場將以 10.9% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	3.452億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	10.90%	2033年市場規模預測：	7.122億美元

慢性腎臟病（CKD）患者的發生率、死亡率、住院率和醫療服務利用率均顯著高於正常人。慢性腎臟病可能由高血壓等合併症引起，導致代謝廢物在患者血液中積聚，從而損害健康狀況。慢性腎臟病的併發症包括高血壓、貧血（血球計數低）、骨質疏鬆、營養不良和神經病變。慢性腎臟病也會增加心血管疾病（如心肌梗塞和中風）的風險。這些問題可能在長期內逐漸加重。

市場動態

各大公司正在公佈抗高血壓藥物的臨床試驗結果，以尋找治療慢性腎臟病病患者高血壓的方法。例如，2018年，諾華國際公司宣布其藥物「Entresto（沙庫巴曲/Valsartan）」取得了積極的臨床試驗結果。根據該公司的臨床試驗，「Entresto（沙庫巴曲/Valsartan）」有助於維持心血管疾病患者的腎功能。此外，「Entresto（沙庫巴曲/Valsartan）」被歸類為血管收縮素受體阻斷劑（ARB）。

接受透析治療的患者人數不斷增加，預計將推動全球慢性腎臟病（CKD）相關高血壓市場的成長。例如，根據《印度公共衛生雜誌》（IJPH）發表的數據，2018年印度約有13萬名患者接受透析治療，與2017年相比，每百萬人中增加了約232人。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、區域前景以及主要參與者採取的競爭策略。
本研究根據以下參數對全球與慢性腎臟病 (CKD) 相關的高血壓市場的主要參與者進行了分析：公司概況、財務業績、產品系列、企業發展區域、分銷策略、關鍵發展和策略以及未來計劃。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
這份關於「與慢性腎病相關的高血壓」的全球市場報告針對的是行業內的各種相關人員，包括投資者、供應商、製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析與慢性腎臟病 (CKD) 相關的高血壓市場時所使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

公司簡介
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- AstraZeneca Plc
- Novartis International AG
- CH Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd.
- KBP Biosciences Holdings Limited
- Ardelyx
- Reata Pharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd
- Pfizer Inc.
- Bayer Pharmaceuticals, Inc
- GSK plc.

第8章

參考
調查方法

簡介目錄

Product Code: CMI4431

Hypertension in CKD Market is estimated to be valued at USD 345.2 Mn in 2026 and is expected to reach USD 712.2 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 345.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	10.90%	2033 Value Projection:	USD 712.2 Mn

Persons with CKD have significantly higher rates of morbidity, mortality, hospitalizations, and healthcare utilization. Chronic kidney disease may be caused due to comorbid conditions such as high blood pressure, etc. This can lead to buildup of metabolic wastes in patient's blood and make them feel sick. Chronic kidney disease complications include high blood pressure, anemia (low blood count), weak bones, poor nutritional health, and nerve damage. Chronic kidney disease also increases the risk of developing heart and blood vessel diseases such as heart attack, stroke, etc. These problems may happen slowly over a long period of time.

Market Dynamics

Key players are involved in announcing their results for the clinical trials conducted for the antihypertensive drugs, in order to find the treatment for hypertension in patients suffering from chronic kidney disease. For instance, in 2018, Novartis International AG announced positive results for Entresto (sacubitril/valsartan). According to the clinical trials conducted by the company, it was found that Entresto (sacubitril/valsartan) helped to preserve kidney function in patients suffering from cardiovascular diseases. Moreover, Entresto (sacubitril/valsartan) belongs to angiotensin receptor blockers (ARBs) drug class.

The increasing number of patients undergoing dialysis treatment is expected to drive growth of the global hypertension in CKD market. For instance, according to the data published in the Indian Journal of Public Health (IJPH), in 2018, around 130,000 patients received dialysis treatment in India and the number increased by around 232 patients per million population in India as compared to 2017.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global hypertension in CKD market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global hypertension in CKD market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the hypertension in CKD market

Detailed Segmentation:

Global Hypertension in CKD Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
Diuretics
RAS Blockade
B - Blockers
Calcium Channel Blockers
Others
Global Hypertension in CKD Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hypertension in CKD Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Drug Class:
  - Diuretics
  - RAS Blockade
  - B - Blockers
  - Calcium Channel Blockers
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - U.S.
  - Canada
Latin America
- By Drug Class:
  - Diuretics
  - RAS Blockade
  - B - Blockers
  - Calcium Channel Blockers
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Drug Class:
  - Diuretics
  - RAS Blockade
  - B - Blockers
  - Calcium Channel Blockers
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - U.K.
  - Germany
  - Italy
  - Spain
  - France
  - Russia
  - Rest of Europe
Asia Pacific
- By Drug Class:
  - Diuretics
  - RAS Blockade
  - B - Blockers
  - Calcium Channel Blockers
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - Australia
  - India
  - China
  - Japan
  - ASEAN
  - South Korea
  - Rest of Asia Pacific
Middle East
- By Drug Class:
  - Diuretics
  - RAS Blockade
  - B - Blockers
  - Calcium Channel Blockers
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Drug Class:
  - Diuretics
  - RAS Blockade
  - B - Blockers
  - Calcium Channel Blockers
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Sanofi S.A*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
Teva Pharmaceutical Industries Ltd.
Eli Lilly and Company
AstraZeneca Plc
Novartis International AG
H. Boehringer Sohn AG & Ko. KG
Kissei Pharmaceutical Co., Ltd.
Reata Pharmaceuticals, Inc.
Ardelyx,
KBP Biosciences Holdings Limited

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Key Developments
Pipeline analysis
Regulatory Scenario
Key Developments
Treatment Approaches
PEST Analysis

4. Global Hypertension in CKD Market, By Drug Class, 2021 - 030, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
RAS Blockade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
β-Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Others (α-Blockers, Vasodilators, Proteinuria, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends

5. Global Hypertension in CKD Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

6. Global Hypertension in CKD Market, By Region, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2021 -2033, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Company Profiles
- Sanofi S.A
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eli Lilly and Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AstraZeneca Plc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis International AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- KBP Biosciences Holdings Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Ardelyx
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Reata Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Kissei Pharmaceutical Co., Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bayer Pharmaceuticals, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- GSK plc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies

8. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

高血壓流行病學分析與預測：2026-2035年

Telmisartan市場報告：按適應症、分銷管道和地區分類（2026-2034 年）

Telmisartan市場：依成分、適應症、劑型、通路和地區分類

FAQ

慢性腎病高血壓市場：按藥物類別、分銷管道和地區分類